Targeting enabled homolog with daunorubicin inhibits ERK1/2/c‐Fos pathway and suppresses hepatocellular carcinoma progression
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | Clinical and Translational Medicine |
| Online Access: | https://doi.org/10.1002/ctm2.70366 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849434949045714944 |
|---|---|
| author | Zhi‐Mei Li Guan Liu Qing‐Qing Liu Wei‐Ming You Ming‐Gao Zhao |
| author_facet | Zhi‐Mei Li Guan Liu Qing‐Qing Liu Wei‐Ming You Ming‐Gao Zhao |
| author_sort | Zhi‐Mei Li |
| collection | DOAJ |
| format | Article |
| id | doaj-art-18eea015fe8446c48e8ddd5e79ea295d |
| institution | Kabale University |
| issn | 2001-1326 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Medicine |
| spelling | doaj-art-18eea015fe8446c48e8ddd5e79ea295d2025-08-20T03:26:29ZengWileyClinical and Translational Medicine2001-13262025-06-01156n/an/a10.1002/ctm2.70366Targeting enabled homolog with daunorubicin inhibits ERK1/2/c‐Fos pathway and suppresses hepatocellular carcinoma progressionZhi‐Mei Li0Guan Liu1Qing‐Qing Liu2Wei‐Ming You3Ming‐Gao Zhao4Institute of Medical Research, Northwestern Polytechnical University Xi'an Shaanxi ChinaDepartment of Pharmacy Tangdu Hospital, Fourth Military Medical University Xi'an Shaanxi ChinaDepartment of Pharmacy Tangdu Hospital, Fourth Military Medical University Xi'an Shaanxi ChinaDepartment of infectious Diseases Department of Tumor and Immunology in Precision Medical Institute and Western China Science and Technology Innovation Port The Second Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi ChinaInstitute of Medical Research, Northwestern Polytechnical University Xi'an Shaanxi Chinahttps://doi.org/10.1002/ctm2.70366 |
| spellingShingle | Zhi‐Mei Li Guan Liu Qing‐Qing Liu Wei‐Ming You Ming‐Gao Zhao Targeting enabled homolog with daunorubicin inhibits ERK1/2/c‐Fos pathway and suppresses hepatocellular carcinoma progression Clinical and Translational Medicine |
| title | Targeting enabled homolog with daunorubicin inhibits ERK1/2/c‐Fos pathway and suppresses hepatocellular carcinoma progression |
| title_full | Targeting enabled homolog with daunorubicin inhibits ERK1/2/c‐Fos pathway and suppresses hepatocellular carcinoma progression |
| title_fullStr | Targeting enabled homolog with daunorubicin inhibits ERK1/2/c‐Fos pathway and suppresses hepatocellular carcinoma progression |
| title_full_unstemmed | Targeting enabled homolog with daunorubicin inhibits ERK1/2/c‐Fos pathway and suppresses hepatocellular carcinoma progression |
| title_short | Targeting enabled homolog with daunorubicin inhibits ERK1/2/c‐Fos pathway and suppresses hepatocellular carcinoma progression |
| title_sort | targeting enabled homolog with daunorubicin inhibits erk1 2 c fos pathway and suppresses hepatocellular carcinoma progression |
| url | https://doi.org/10.1002/ctm2.70366 |
| work_keys_str_mv | AT zhimeili targetingenabledhomologwithdaunorubicininhibitserk12cfospathwayandsuppresseshepatocellularcarcinomaprogression AT guanliu targetingenabledhomologwithdaunorubicininhibitserk12cfospathwayandsuppresseshepatocellularcarcinomaprogression AT qingqingliu targetingenabledhomologwithdaunorubicininhibitserk12cfospathwayandsuppresseshepatocellularcarcinomaprogression AT weimingyou targetingenabledhomologwithdaunorubicininhibitserk12cfospathwayandsuppresseshepatocellularcarcinomaprogression AT minggaozhao targetingenabledhomologwithdaunorubicininhibitserk12cfospathwayandsuppresseshepatocellularcarcinomaprogression |